Advanced Proteomic Technologies for Cancer Research

Leidos Biomedical Research, Inc., Frederick MD

Investigators

Abstract

This funding is in support of the research initiatives in the Clinical Proteomics Technologies for Cancer Program. Specifically, 1) Mouse Biospecimens: To furnish services, equipment, and facilities to manage mouse tissue and plasma samples;2) To conduct characterization assays on antibodies for the CPTC initiative, and made accessible to the research community;3) To provide a caBIG compliant public proteomics data sharing site, and oversea that proper data ontologies and annotations are consistent throughout the CPTC network;4) To support experimental study design, statistical analysis, and methodological approaches to applying proteomic technology platforms toward clinical measurement;5) To determine the statistically correct number of patient biospecimens required at each phase of the CPTC initiative proteomics pipeline;6) To develop antibodies to peptides from specific regions of interest in a cancer related protein